

In Vitro Diagnostics (IVD) Quality Control Market by Product & Service (QC (Plasma, Serum, Blood), Solutions), Technology (Immunoassay, MDx, Microbiology, Hematology), Manufacturer (Third-party, OEM), End User (Hospitals, Labs) - Global Forecast to 2030

Market Report | 2025-09-19 | 379 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The IVD quality controls market is valued at an estimated USD 1.65 billion in 2025 and is projected to reach USD 2.15 billion by 2030, at a CAGR of 5.5% during the forecast period.

<https://www.marketsandmarkets.com/Images/in-vitro-diagnostics-quality-controls-market-Overview.webp>

IVD quality controls play a critical role in ensuring the accuracy, reliability, and consistency of diagnostic test results across clinical laboratories and healthcare facilities. The growing adoption of third-party quality controls is one of the major drivers of the IVD quality controls market. Unlike instrument-specific controls, third-party solutions offer greater flexibility, compatibility across multiple platforms, and longer shelf life. They provide unbiased performance assessment and consistent analyte stability, helping laboratories maintain reproducible and reliable results. With increasing regulatory and accreditation requirements, laboratories are favoring third-party controls to ensure compliance while optimizing workflow efficiency. The rising use of multianalyte controls further enhances demand, allowing simultaneous monitoring of multiple assays and reducing operational costs. Hospitals and clinical laboratories, in particular, are adopting these solutions to support high-volume testing and diverse diagnostic applications. This shift toward third-party quality controls continues to drive innovation, adoption, and sustained growth in the global IVD quality controls market.

"By product & service, the quality control products segment dominated the IVD quality controls market in 2024."

By product & service, the IVD quality controls market is segmented into quality control products, data management solutions, and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

quality assurance services. In 2024, quality control products held the largest share, driven by the increasing number of diagnostic tests and the need for accurate, reliable, and reproducible results. Regulatory and accreditation requirements further support their adoption, as laboratories aim to maintain compliance and ensure patient safety. Quality control products enable consistent performance monitoring across multiple assays and platforms, helping reduce errors and improve workflow efficiency. The rising use of third-party and multianalyte controls has further strengthened this segment, allowing simultaneous testing of multiple analytes while optimizing operational costs. Overall, QC products remain the backbone of laboratory quality management, making them the dominant segment within the IVD quality controls market.

"By manufacturer type, the third-party controls segment is projected to achieve the highest growth during the forecast period."

By manufacturer type, the IVD quality controls market is segmented into third-party controls and original equipment manufacturer (OEM) controls. Third-party controls are projected to be the fastest-growing segment during the forecast period. Their compatibility across multiple platforms, longer shelf life, and unbiased performance assessment make them increasingly preferred by laboratories. Third-party controls also support multianalyte testing and standardized QC procedures, helping laboratories improve workflow efficiency and ensure reproducible results. While OEM controls remain important for instrument-specific applications, the growing demand for versatile, cost-effective, and reliable solutions continues to drive the rapid adoption of third-party controls globally.

"The Asia Pacific is projected to be the fastest-growing regional market during the forecast period."

The market for IVD quality controls is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is anticipated to be the fastest-growing region in the IVD quality controls market during the forecast period, driven by the rapid development of healthcare infrastructure and increasing investment in advanced diagnostic technologies. The region is witnessing a growing number of clinical laboratories, hospitals, and diagnostic centers, which is boosting the demand for reliable and accurate quality control products. Rising awareness about the importance of early disease detection, coupled with regulatory initiatives to improve laboratory standards, is further supporting market growth. Additionally, the expanding patient population and the rising prevalence of chronic and infectious diseases are creating strong demand for quality control solutions to ensure accuracy and reproducibility.

Breakdown of the profiles of primary participants in the IVD quality controls market:

-□By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)

-□By Designation: C-level Executives (27%), Director-level Executives (18%), and Others (55%)

-□By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the IVD quality controls market are Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott (US), LGC Limited (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Randox Laboratories Ltd. (UK), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), Danaher Corporation (US), Sysmex Corporation (Japan), Bio-Techne Corporation (US), Microbix Biosystems Inc. (Canada), Microbiologics, Inc. (US), ZeptoMetrix (US), Fortress Diagnostics (UK), Helena Laboratories Corporation (US), Streck, Inc. (US), SERO AS (Norway), Maine Molecular Quality Controls, Inc. (US), Sun Diagnostics, LLC (US), Alpha-Tec (US), Grifols, S.A. (Spain), ConeBioproducts (US), Eurotrol B.V. (Netherlands), and Biorex Diagnostics (UK).

Research Coverage:

This research report categorizes the IVD quality controls market by product & service (quality control products, data management solutions, and quality assurance services), technology (immunoassays, clinical chemistry, molecular diagnostics, microbiology, hematology, coagulation & hemostasis, and other technologies), manufacturer type [third-party controls ([independent controls, instrument-specific controls), original equipment manufacturer controls], end user (hospitals, clinical laboratories, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the IVD quality controls market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. A competitive analysis of upcoming startups in the IVD quality controls market ecosystem is covered in this report.

Reasons to Buy this Report:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD quality controls market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

-□ Analysis of key drivers (increasing number of accredited clinical laboratories, growing adoption of third-party quality controls, rising demand for external quality assessment support, rising geriatric population and subsequent growth in prevalence of chronic

and infectious diseases, and increasing adoption of PoC instruments in developed regions), opportunities (rising demand for multianalyte controls and increasing growth opportunities in emerging economies), restraints (additional costs and budget constraints in hospitals and laboratories and unfavorable reimbursement scenario for IVD tests), and challenges (stringent product approval process and lack of regulations for clinical laboratory accreditation in several emerging countries) influencing the growth of the IVD quality controls market.

-□ Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the IVD quality controls market

-□ Market Development: Comprehensive information about lucrative markets across varied regions

-□ Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the IVD quality controls market

-□ Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott (US), LGC Limited (UK), and F. Hoffmann-La Roche Ltd. (Switzerland)

Table of Contents:

1	INTRODUCTION	34
1.1	STUDY OBJECTIVES	34
1.2	MARKET DEFINITION	34
1.3	STUDY SCOPE	35
1.3.1	MARKETS COVERED & REGIONAL SCOPE	35
1.4	INCLUSIONS & EXCLUSIONS	36
1.4.1	YEARS CONSIDERED	37
1.5	CURRENCY CONSIDERED	37
1.6	KEY STAKEHOLDERS	37
1.7	SUMMARY OF CHANGES	38
2	RESEARCH METHODOLOGY	39
2.1	RESEARCH DATA	39
2.2	RESEARCH APPROACH	39
2.2.1	SECONDARY DATA	40
2.2.1.1	Key secondary sources	40
2.2.1.2	Key data from secondary sources	41
2.2.2	PRIMARY DATA	42
2.2.2.1	Primary sources	42
2.2.2.2	Key data from primary sources	43
2.2.2.3	Key industry insights	44
2.2.2.4	Breakdown of primary interviews	44
2.3	MARKET SIZE ESTIMATION	45
2.3.1	BOTTOM-UP APPROACH	45

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.3.1.1	Approach 1: Company revenue estimation approach	46
2.3.1.2	Approach 2: Presentations of companies and primary interviews	46
2.3.1.3	Growth forecast	46
2.3.1.4	CAGR projections	47
2.3.2	TOP-DOWN APPROACH	47
2.4	MARKET BREAKDOWN & DATA TRIANGULATION	49
2.5	MARKET SHARE ASSESSMENT	49
2.6	RESEARCH ASSUMPTIONS	50
2.6.1	PARAMETRIC ASSUMPTIONS	50
2.7	RESEARCH LIMITATIONS	50
2.8	RISK ASSESSMENT	51
3	EXECUTIVE SUMMARY	52
?		
4	PREMIUM INSIGHTS	56
4.1	IVD QUALITY CONTROLS MARKET OVERVIEW	56
4.2	IVD QUALITY CONTROLS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030	57
4.3	IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2025 VS. 2030	57
4.4	IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2025 VS. 2030	58
4.5	IVD QUALITY CONTROLS MARKET, BY END USER, 2025 VS. 2030	58
4.6	IVD QUALITY CONTROLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	59
5	MARKET OVERVIEW	60
5.1	INTRODUCTION	60
5.2	MARKET DYNAMICS	60
5.2.1	DRIVERS	61
5.2.1.1	Increasing number of accredited clinical laboratories	61
5.2.1.2	Growing adoption of third-party quality controls	62
5.2.1.3	Rising demand for external quality assessment support	62
5.2.1.4	Rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases	63
5.2.1.5	Increasing adoption of POC instruments in developed regions	64
5.2.2	RESTRAINTS	65
5.2.2.1	Additional costs and budget constraints in hospitals and laboratories	65
5.2.2.2	Unfavorable reimbursement scenario for IVD tests	65
5.2.3	OPPORTUNITIES	66
5.2.3.1	Rising demand for multianalyte controls	66
5.2.3.2	Increasing growth opportunities in emerging economies	66
5.2.4	CHALLENGES	67
5.2.4.1	Stringent product approval process	67
5.2.4.2	Lack of regulations for clinical laboratory accreditation in several emerging countries	67
5.3	PRICING ANALYSIS	68
5.3.1	AVERAGE SELLING PRICE TREND OF IVD QUALITY CONTROL PRODUCTS, 2023-2025	68
5.3.2	AVERAGE SELLING PRICE TREND OF IVD QUALITY CONTROLS, BY KEY PLAYER, 2023-2025	68
5.3.3	AVERAGE SELLING PRICE TREND OF IVD QUALITY CONTROL PRODUCTS, BY REGION, 2023-2025	70
5.4	PATENT ANALYSIS	71
5.4.1	LIST OF MAJOR PATENTS	72
5.5	VALUE CHAIN ANALYSIS	73
5.6	SUPPLY CHAIN ANALYSIS	74

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.7 □ TRADE ANALYSIS □ 75
- 5.7.1 □ IMPORT DATA (HS CODE 3822) □ 76
- 5.7.2 □ EXPORT DATA (HS CODE 3822) □ 76
- ?
- 5.8 □ ECOSYSTEM ANALYSIS □ 77
- 5.8.1 □ IVD QUALITY CONTROLS MARKET: ROLE OF COMPANIES IN ECOSYSTEM □ 78
- 5.9 □ PORTER'S FIVE FORCES ANALYSIS □ 79
- 5.9.1 □ THREAT OF NEW ENTRANTS □ 80
- 5.9.2 □ THREAT OF SUBSTITUTES □ 80
- 5.9.3 □ BARGAINING POWER OF BUYERS □ 80
- 5.9.4 □ BARGAINING POWER OF SUPPLIERS □ 80
- 5.9.5 □ INTENSITY OF COMPETITIVE RIVALRY □ 80
- 5.10 □ REGULATORY ANALYSIS □ 81
- 5.10.1 □ REGULATORY FRAMEWORK □ 81
- 5.10.1.1 □ North America □ 81
- 5.10.1.1.1 □ US □ 81
- 5.10.1.1.2 □ Canada □ 82
- 5.10.1.2 □ Europe □ 83
- 5.10.1.2.1 □ Germany □ 84
- 5.10.1.2.2 □ UK □ 84
- 5.10.1.2.3 □ France □ 85
- 5.10.1.2.4 □ Italy □ 85
- 5.10.1.3 □ Asia Pacific □ 85
- 5.10.1.3.1 □ China □ 85
- 5.10.1.3.2 □ Japan □ 85
- 5.10.1.3.3 □ India □ 86
- 5.10.1.4 □ Latin America □ 87
- 5.10.1.4.1 □ Brazil □ 87
- 5.10.1.4.2 □ Mexico □ 87
- 5.10.1.5 □ Middle East □ 88
- 5.10.1.6 □ Africa □ 88
- 5.10.2 □ REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS □ 88
- 5.11 □ TECHNOLOGY ANALYSIS □ 90
- 5.11.1 □ KEY TECHNOLOGIES □ 91
- 5.11.1.1 □ Immunoassays □ 91
- 5.11.2 □ COMPLEMENTARY TECHNOLOGIES □ 91
- 5.11.2.1 □ Molecular diagnostics □ 91
- 5.11.3 □ ADJACENT TECHNOLOGIES □ 92
- 5.11.3.1 □ Clinical chemistry □ 92
- 5.12 □ KEY CONFERENCES & EVENTS, 2025-2026 □ 92
- 5.13 □ TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES □ 93
- 5.14 □ KEY STAKEHOLDERS & BUYING CRITERIA □ 94
- 5.14.1 □ KEY STAKEHOLDERS IN BUYING PROCESS □ 94
- 5.14.2 □ BUYING CRITERIA □ 94
- ?
- 5.15 □ INVESTMENT & FUNDING SCENARIO □ 95
- 5.16 □ CASE STUDY ANALYSIS □ 96

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.16.1	CASE STUDY 1: QUALITY CONTROL DATA MANAGEMENT WITH UNITY REAL-TIME IN MOLECULAR VIROLOGY	96
5.16.2	CASE STUDY 2: ENHANCING RELIABILITY OF INFLUENZA DIAGNOSTICS WITH EXTERNAL QUALITY CONTROLS	96
5.17	IMPACT OF AI/GENERATIVE AI ON IVD QUALITY CONTROLS MARKET	97
5.17.1	INTRODUCTION	97
5.17.2	MARKET POTENTIAL OF AI	97
5.17.3	AI USE CASES	98
5.17.4	IMPLEMENTATION OF AI, BY KEY COMPANY AND USE CASE	99
5.17.5	FUTURE OF AI IN IVD QUALITY CONTROLS MARKET	99
5.18	IMPACT OF 2025 US TARIFFS ON IVD QUALITY CONTROLS MARKET	99
5.18.1	INTRODUCTION	99
5.18.2	KEY TARIFF RATES	100
5.18.3	PRICE IMPACT ANALYSIS	100
5.18.4	IMPACT ON COUNTRY/REGION	101
5.18.4.1	North America	101
5.18.4.2	Europe	101
5.18.4.3	Asia Pacific	101
5.18.5	IMPACT ON END-USE INDUSTRIES	101
5.18.5.1	Hospitals	101
5.18.5.2	Clinical laboratories	102
5.18.5.3	Academic & research institutes	102
6	IVD QUALITY CONTROLS MARKET, BY PRODUCT & SERVICE	103
6.1	INTRODUCTION	104
6.2	QUALITY CONTROL PRODUCTS	104
6.2.1	SERUM/PLASMA-BASED CONTROLS	108
6.2.1.1	Greater stability and accuracy of diagnostic test results to increase demand for serum/plasma-based controls	108
6.2.2	WHOLE BLOOD-BASED CONTROLS	112
6.2.2.1	Rising need to ensure high-quality clinical test results to drive market	112
6.2.3	URINE-BASED CONTROLS	115
6.2.3.1	Growing incidence of kidney diseases to drive demand for urine-based controls	115
6.2.4	OTHER CONTROLS	119
6.3	DATA MANAGEMENT SOLUTIONS	123
6.3.1	RIISING FOCUS ON IMPROVING ANALYTICAL PERFORMANCE OF CLINICAL LABORATORIES TO SUPPORT MARKET GROWTH	123
6.4	QUALITY ASSURANCE SERVICES	126
6.4.1	GROWING NEED FOR PERFORMANCE ASSESSMENT OF CLINICAL LABORATORIES TO INCREASE DEMAND FOR QUALITY ASSURANCE SERVICES	126
7	IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY	129
7.1	INTRODUCTION	130
7.2	IMMUNOASSAYS	130
7.2.1	FOCUS ON MONITORING PRECISION OF IMMUNOASSAY TESTS TO DRIVE ADOPTION OF IMMUNOASSAY CONTROLS	130
7.3	CLINICAL CHEMISTRY	134
7.3.1	RIISING INCIDENCE OF LIFESTYLE DISEASES TO PROVIDE OPPORTUNITIES FOR MARKET GROWTH	134
7.4	MOLECULAR DIAGNOSTICS	138
7.4.1	GROWING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE DEMAND FOR MOLECULAR DIAGNOSTIC CONTROLS	138
7.5	MICROBIOLOGY	142
7.5.1	INCREASING ADOPTION OF AUTOMATED CLINICAL MICROBIOLOGY TESTING INSTRUMENTS TO SUPPORT MARKET GROWTH	142

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.6	HEMATOLOGY	146
7.6.1	NEED FOR ACCURACY IN HEMATOLOGICAL TEST RESULTS TO DRIVE RELIANCE ON HEMATOLOGY QUALITY CONTROLS	146
7.7	COAGULATION & HEMOSTASIS	150
7.7.1	GROWING NUMBER OF CARDIOVASCULAR SURGERIES TO DRIVE DEMAND FOR COAGULATION & HEMOSTASIS TESTING	150
7.8	OTHER TECHNOLOGIES	153
8	IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE	157
8.1	INTRODUCTION	158
8.2	THIRD-PARTY CONTROLS	158
8.2.1	INDEPENDENT CONTROLS	162
8.2.1.1	Unbiased and independent performance assessment for analytical processes to drive adoption	162
8.2.2	INSTRUMENT-SPECIFIC CONTROLS	165
8.2.2.1	Dependence on instrument-specific compatibility to restrict demand	165
8.3	ORIGINAL EQUIPMENT MANUFACTURER CONTROLS	168
8.3.1	OEM CONTROLS TO WITNESS LOWER ADOPTION AS THEY ARE LESS SENSITIVE TO QC-RELATED ISSUES	168
9	IVD QUALITY CONTROLS MARKET, BY END USER	172
9.1	INTRODUCTION	173
9.2	HOSPITALS	173
9.2.1	LARGE VOLUME OF IVD PROCEDURES PERFORMED TO DRIVE MARKET	173
9.3	CLINICAL LABORATORIES	176
9.3.1	GROWING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET	176
9.4	ACADEMIC & RESEARCH INSTITUTES	179
9.4.1	RIISING FOCUS ON ACCURATE RESEARCH RESULTS TO SUPPORT MARKET GROWTH	179
9.5	OTHER END USERS	182
10	IVD QUALITY CONTROLS MARKET, BY REGION	186
10.1	INTRODUCTION	187
10.2	NORTH AMERICA	187
10.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	192
10.2.2	US	192
10.2.2.1	High healthcare expenditure to propel market growth	192
10.2.3	CANADA	195
10.2.3.1	Government initiatives and research funding to support market growth	195
10.3	EUROPE	198
10.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	202
10.3.2	GERMANY	202
10.3.2.1	Rising volume of high-quality tests performed to support market growth	202
10.3.3	UK	205
10.3.3.1	Growing number of diagnostic centers to drive market	205
10.3.4	FRANCE	208
10.3.4.1	Increasing prevalence of infectious diseases and growing demand for early diagnosis to drive market	208
10.3.5	ITALY	211
10.3.5.1	Growing disease prevalence to drive demand for better and more accurate disease diagnosis	211
10.3.6	SPAIN	213
10.3.6.1	Rising incidence of chronic diseases to support market growth	213
10.3.7	RUSSIA	216
10.3.7.1	Increasing access to quality healthcare and growing incidence of lifestyle and infectious diseases to drive market	216
10.3.8	REST OF EUROPE	219
10.4	ASIA PACIFIC	222

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 227
- 10.4.2 CHINA 227
 - 10.4.2.1 Growing access to modern healthcare and government support to boost market growth 227
- 10.4.3 JAPAN 230
 - 10.4.3.1 Well-developed healthcare system and demand for improvements in quality of IVD test results to drive market 230
- 10.4.4 INDIA 233
 - 10.4.4.1 Rising need to secure NABL accreditations to drive demand for quality controls 233
- 10.4.5 AUSTRALIA 236
 - 10.4.5.1 Initiatives to enhance access to healthcare and improve infrastructure to propel market growth 236
- 10.4.6 SOUTH KOREA 239
 - 10.4.6.1 Rising healthcare expenditure and growing number of hospitals to drive market 239
- 10.4.7 REST OF ASIA PACIFIC 242
- 10.5 LATIN AMERICA 245
 - 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 249
 - 10.5.2 BRAZIL 249
 - 10.5.2.1 Brazil to dominate Latin American IVD quality controls market 249
 - 10.5.3 MEXICO 252
 - 10.5.3.1 Increasing number of accredited clinical laboratories to support market growth 252
 - 10.5.4 REST OF LATIN AMERICA 255
- 10.6 MIDDLE EAST & AFRICA 258
 - 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 262
 - 10.6.2 SAUDI ARABIA 262
 - 10.6.2.1 Rising government healthcare expenditure to boost market 262
 - 10.6.3 UAE 265
 - 10.6.3.1 Improvements in healthcare infrastructure to support growth 265
 - 10.6.4 REST OF MIDDLE EAST & AFRICA 268
- 11 COMPETITIVE LANDSCAPE 272
 - 11.1 INTRODUCTION 272
 - 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 272
 - 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN IVD QUALITY CONTROLS MARKET 273
 - 11.3 REVENUE ANALYSIS, 2022-2024 275
 - 11.4 MARKET SHARE ANALYSIS, 2024 276
 - 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 278
 - 11.5.1 STARS 278
 - 11.5.2 EMERGING LEADERS 278
 - 11.5.3 PERVASIVE PLAYERS 278
 - 11.5.4 PARTICIPANTS 278
 - 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 280
 - 11.5.5.1 Company footprint 280
 - 11.5.5.2 Region footprint 281
 - 11.5.5.3 Product & service footprint 282
 - 11.5.5.4 Technology footprint 283
 - 11.5.5.5 Manufacturer type footprint 284
 - 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 285
 - 11.6.1 PROGRESSIVE COMPANIES 285
 - 11.6.2 RESPONSIVE COMPANIES 285
 - 11.6.3 DYNAMIC COMPANIES 285

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.6.4	STARTING BLOCKS	285
11.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	287
11.6.5.1	Detailed list of key startups/SMEs	287
11.6.5.2	Competitive benchmarking of key emerging players/startups, by product & service and manufacturer type	287
11.6.5.3	Competitive benchmarking of key startups/SMEs, by region	288
11.7	COMPANY VALUATION & FINANCIAL METRICS	288
11.7.1	FINANCIAL METRICS	288
11.7.2	COMPANY VALUATION	289
11.8	BRAND/PRODUCT COMPARISON	289
11.8.1	BRAND/PRODUCT COMPARATIVE ANALYSIS	289
11.9	COMPETITIVE SCENARIO	290
11.9.1	PRODUCT & SERVICE LAUNCHES AND APPROVALS	290
11.9.2	DEALS	291
11.9.3	EXPANSIONS	292
12	COMPANY PROFILES	293
12.1	KEY PLAYERS	293
12.1.1	BIO-RAD LABORATORIES, INC.	293
12.1.1.1	Business overview	293
12.1.1.2	Products & services offered	294
12.1.1.3	Recent developments	299
12.1.1.3.1	Product & service launches	299
12.1.1.3.2	Deals	299
12.1.1.4	MnM view	299
12.1.1.4.1	Key strengths	299
12.1.1.4.2	Strategic choices	300
12.1.1.4.3	Weaknesses & competitive threats	300
12.1.2	THERMO FISHER SCIENTIFIC, INC.	301
12.1.2.1	Business overview	301
12.1.2.2	Products & services offered	302
12.1.2.3	Recent developments	304
12.1.2.3.1	Deals	304
12.1.2.4	MnM view	305
12.1.2.4.1	Key strengths	305
12.1.2.4.2	Strategic choices	305
12.1.2.4.3	Weaknesses & competitive threats	305
12.1.3	ABBOTT	306
12.1.3.1	Business overview	306
12.1.3.2	Products & services offered	307
12.1.3.3	MnM view	309
12.1.3.3.1	Key strengths	309
12.1.3.3.2	Strategic choices	309
12.1.3.3.3	Weaknesses & competitive threats	309
	?	
12.1.4	LGC LIMITED	310
12.1.4.1	Business overview	310
12.1.4.2	Products & services offered	311

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.1.4.3	Recent developments	314
12.1.4.3.1	Deals	314
12.1.4.4	MnM view	315
12.1.4.4.1	Key strengths	315
12.1.4.4.2	Strategic choices	315
12.1.4.4.3	Weaknesses & competitive threats	315
12.1.5	F. HOFFMANN-LA ROCHE LTD.	316
12.1.5.1	Business overview	316
12.1.5.2	Products & services offered	317
12.1.5.3	Recent developments	318
12.1.5.3.1	Deals	318
12.1.5.4	MnM view	319
12.1.5.4.1	Key strengths	319
12.1.5.4.2	Strategic choices	319
12.1.5.4.3	Weaknesses & competitive threats	319
12.1.6	RANDOX LABORATORIES LTD.	320
12.1.6.1	Business overview	320
12.1.6.2	Products & services offered	320
12.1.6.3	Recent developments	324
12.1.6.3.1	Product & service launches	324
12.1.6.3.2	Deals	324
12.1.7	SIEMENS HEALTHINEERS AG	325
12.1.7.1	Business overview	325
12.1.7.2	Products & services offered	326
12.1.8	QUIDELORTHO CORPORATION	327
12.1.8.1	Business overview	327
12.1.8.2	Products & services offered	328
12.1.8.3	Recent developments	330
12.1.8.3.1	Deals	330
12.1.8.3.2	Expansions	330
12.1.9	DANAHER CORPORATION	331
12.1.9.1	Business overview	331
12.1.9.2	Products & services offered	332
12.1.10	SYSMEX CORPORATION	334
12.1.10.1	Business overview	334
12.1.10.2	Products & services offered	335
12.1.10.3	Recent developments	336
12.1.10.3.1	Product & service launches	336
12.1.10.3.2	Deals	336
12.1.10.3.3	Expansions	337
12.1.11	BIO-TECHNE CORPORATION	339
12.1.11.1	Business overview	339
12.1.11.2	Products & services offered	340
12.1.11.3	Recent developments	344
12.1.11.3.1	Product & service launches	344
12.1.11.3.2	Deals	344
12.1.11.3.3	Expansions	345

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.1.12	MICROBIX BIOSYSTEMS INC.	346
12.1.12.1	Business overview	346
12.1.12.2	Products & services offered	347
12.1.12.3	Recent developments	348
12.1.12.3.1	Product & service launches	348
12.1.12.3.2	Deals	349
12.1.13	GRIFOLS, S.A.	351
12.1.13.1	Business overview	351
12.1.13.2	Products & services offered	352
12.1.14	MICROBIOLOGICS, INC.	353
12.1.14.1	Business overview	353
12.1.14.2	Products & services offered	353
12.1.14.3	Recent developments	355
12.1.14.3.1	Deals	355
12.1.15	ZEPTOMETRIX	356
12.1.15.1	Business overview	356
12.1.15.2	Products & services offered	356
12.1.15.3	Recent developments	357
12.1.15.3.1	Product & service launches & approvals	357
12.1.16	FORTRESS DIAGNOSTICS	359
12.1.16.1	Business overview	359
12.1.16.2	Products & services offered	359
12.2	OTHER PLAYERS	362
12.2.1	HELENA LABORATORIES CORPORATION	362
12.2.2	STRECK, INC.	363
12.2.3	MAINE MOLECULAR QUALITY CONTROLS, INC.	364
12.2.4	SUN DIAGNOSTICS, LLC	366
12.2.5	SERO AS	366
12.2.6	CONEBIOPRODUCTS	367
12.2.7	ALPHA-TEC	368
12.2.8	EUROTROL B.V.	369
12.2.9	BIOREX DIAGNOSTICS	370
?		
13	APPENDIX	371
13.1	DISCUSSION GUIDE	371
13.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	375
13.3	CUSTOMIZATION OPTIONS	377
13.4	RELATED REPORTS	377
13.5	AUTHOR DETAILS	378

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

In Vitro Diagnostics (IVD) Quality Control Market by Product & Service (QC (Plasma, Serum, Blood), Solutions), Technology (Immunoassay, MDx, Microbiology, Hematology), Manufacturer (Third-party, OEM), End User (Hospitals, Labs) - Global Forecast to 2030

Market Report | 2025-09-19 | 379 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code*

Country*

Date

2026-03-05

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com